Gay News Network, Wednesday 18 January 2017
The Victorian AIDS Council has announced it will give an additional $100,000 to the PrEPX trial to fund access to pre-exposure prophylaxis for HIV (PrEP) for 600 Victorians at risk.
VAC’s announcement comes months after PrEPX reached capacity for men living in
metropolitan Melbourne. The VAC said there is already a substantial waiting list for those wishing to access PrEP as part of the trial.
Australian Federation of AIDS Organisations (AFAO), 23 August, 2016
Following the Pharmaceutical Benefits Advisory Committee (PBAC) decision not to recommend funding PrEP through the Pharmaceutical Benifits Scheme (PBS), AFAO has produced an Australian PrEP roundup paper to sustain advocacy efforts and to raise awareness about current options for accessing PrEP around the country.
In releasing their decision, the PBAC has said they accept the importance of PrEP but were unable to recommend it for a number of reasons, including the cost-effectiveness of the price submitted by Gilead Sciences.
Despite this setback, AFAO will continue with community advocacy to have Gilead Sciences resubmit its application as soon as possible. Interim PrEP access arrangements remain crucial in the meantime.
Hepatitis SA, April 2015
The Pharmaceutical Benefit Advisory Committee has recommended three new drugs for treatment of hepatitis C.
Read more here